These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 30597502)
1. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity. Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502 [TBL] [Abstract][Full Text] [Related]
2. Enhanced clot lysis by a single point mutation in a reteplase variant. Chen S; Chen D; Liu Y; Xu Y; Lin H; Cheng Y; Li J; Meng C; Liang M; Yuan C; Huang M Br J Haematol; 2022 Feb; 196(4):1076-1085. PubMed ID: 34783361 [TBL] [Abstract][Full Text] [Related]
3. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation. Singh S; Houng A; Reed GL Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005 [TBL] [Abstract][Full Text] [Related]
4. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954 [TBL] [Abstract][Full Text] [Related]
6. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706 [TBL] [Abstract][Full Text] [Related]
7. A low bleeding risk thrombolytic agent: citPA5. Chen S; Fang S; Zhou Y; Huang Z; Yu S; Chen D; Wang Z; Xu Y; Liu P; Li Y; Lin W; Jiang L; Yuan C; Huang M Cardiovasc Res; 2024 Sep; 120(10):1191-1201. PubMed ID: 38546342 [TBL] [Abstract][Full Text] [Related]
8. Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M Data Brief; 2016 Mar; 6():550-5. PubMed ID: 26909366 [TBL] [Abstract][Full Text] [Related]
9. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258 [TBL] [Abstract][Full Text] [Related]
10. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow. Graham DA; Huang TC; Keyt BA; Alevriadou BR Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163 [TBL] [Abstract][Full Text] [Related]
11. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. Jankun J; Keck R; Selman SH; Skrzypczak-Jankun E Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488 [TBL] [Abstract][Full Text] [Related]
12. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459 [TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
15. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454 [TBL] [Abstract][Full Text] [Related]